ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Cardiovascular Disease

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,347Medicare Part D Prescriptions Filled, Including Refills

Rank: 33 out of 1442

$881K Total Retail Price of All Prescriptions

Rank: 29 out of 1442

469 Patients Receiving at Least One Drug in Part D
75%Patients 65 Years and Older
84% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New York
Lower avg

Schedule Two
Controlled Substances

17% of this provider’s 469 patients filled at least one prescription for a schedule two drug, compared to an average of 0%.

Schedule Three
Controlled Substances

4% of this provider’s 469 patients filled at least one prescription for a schedule three drug, compared to an average of 0%.

Risky Drugs to Seniors

3% of this provider’s 7,676 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 0%.

Brand Name Drugs

39% of this provider’s prescriptions were for brand-name drugs, compared to an average of 31%.

Prescription Price

$85 was the average price of a prescription from this provider, compared to $75 among peers.

Prescriptions per Patient

22 is the average number of prescriptions (including refills) per patient, compared to an average of 11.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New York
LOVAZA 371 285 1 37
FUROSEMIDE 362 290 2 5
SIMVASTATIN 352 322 3 2
AMLODIPINE BESYLATE 320 266 4 3
METOPROLOL TARTRATE 319 254 5 6
PLAVIX 313 258 6 14
NEXIUM 284 194 7 34
ZOLPIDEM TARTRATE 257 173 8 25
ENALAPRIL MALEATE 211 191 9 23
CARVEDILOL 153 128 10 8
METOPROLOL SUCCINATE 152 128 11 1
CRESTOR 151 104 12 10
HYDROCHLOROTHIAZIDE 147 99 13 16
OMEPRAZOLE 140 105 14 21
METFORMIN HCL 140 88 14 26
CIPROFLOXACIN HCL 138 104 16 103
WARFARIN SODIUM 126 106 17 9
LEVOTHYROXINE SODIUM 123 104 18 22
CLOPIDOGREL 120 112 19 12
MELOXICAM 117 89 20 92
ATENOLOL 112 74 21 11
LISINOPRIL 107 71 22 7
OXYCODONE HCL 99 41 S2 23 280
MECLIZINE HCL 99 80 23 83
DIGOXIN 98 80 25 15
RANEXA 97 64 26 29
CLOTRIMAZOLE-BETAMETHASONE 95 79 27 118
ATORVASTATIN CALCIUM 95 61 27 4
SINGULAIR 95 66 27 93
AMLODIPINE BESYLATE-BENAZEPRIL 95 74 27 43
BYSTOLIC 90 61 31 32
PROMETHAZINE HCL 89 69 R 32 204
DICLOFENAC SODIUM 88 57 33 186
ENDOCET 87 36 S2 34 252
DIPYRIDAMOLE 85 72 R 35 293
VENTOLIN HFA 82 50 36 175
TRAMADOL HCL 80 54 37 97
JANUMET 78 58 38 109
OXYCODONE HCL-ACETAMINOPHEN 70 43 S2 39 308
TAMSULOSIN HCL 69 60 40 38
GLIPIZIDE 66 52 41 120
ISOSORBIDE MONONITRATE ER 65 54 42 17
POTASSIUM CHLORIDE 65 53 42 33
AZITHROMYCIN 61 43 44 56
DIOVAN 60 57 45 19
HYDROCODONE-ACETAMINOPHEN 60 27 S3 45 84
OXYCONTIN 60 33 S2 45 332
IBUPROFEN 59 33 48 130
LIDODERM 55 33 49 76
PROAIR HFA 54 38 50 123
LIPITOR 54 43 50 24
METOLAZONE 52 42 52 113
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on April 28, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.